---
title: "Pharmaceutical manufacturers: Industry Risk Guide"
description: "Pharmaceutical manufacturers make active ingredients and turn them into tablets, capsules, liquids, injectables and biologics under validated, tightly…"
url: https://www.urbanstat.com/industry-risk-guides/pharmaceutical-manufacturers/
type: Industry risk guide: UrbanStat’s underwriting guide for one business type
publisher: UrbanStat
---

# Pharmaceutical manufacturers

Pharmaceutical manufacturers make active ingredients and turn them into tablets, capsules, liquids, injectables and biologics under validated, tightly regulated conditions. Product harm and recall dominate the account, while clean rooms, solvent processes and long requalification times mean a small fire or contamination event becomes a very large loss.

Manufacturing · NAICS 325412 · SIC 2834 · Updated November 2026

Risk profile

1. [Property High](#line-property)
2. [Business interruption High](#line-bi)
3. [Premises liability Moderate](#line-gl)
4. [Products and completed work Severe](#line-products)
5. [Workers’ injury Elevated](#line-wc)
6. [Commercial auto Moderate](#line-auto)
7. [Crime and theft Elevated](#line-crime)
8. [Inland marine and equipment High](#line-marine)
9. [Environmental Elevated](#line-env)
10. [Cyber and data High](#line-cyber)
11. [Professional liability Elevated](#line-prof)
12. [Umbrella and excess Severe](#line-umbrella)

**Products and completed work.** Medicines act on the body by design, reach huge numbers of patients, and failures bring mass litigation and costly recalls.

Loss drivers

## Where losses come from.

1. Injury from side effects, contamination, wrong strength or mislabeling, often as mass claims
2. Smoke, water or microbial contamination of clean rooms and high-value batches
3. Long shutdowns while damaged or contaminated lines are rebuilt, revalidated and reapproved

How it compares Each line’s rating against the average for its NAICS sector, Manufacturing (178 business types), and for all 747.

- Pharmaceutical manufacturers
- Sector average
- All business types

**Low** **Moderate** **Elevated** **High** **Severe**

1. Property Property Property: High, 4 of 5; sector average 3.7; all business types 2.9.
2. Business interruption Interruption Business interruption: High, 4 of 5; sector average 3.5; all business types 2.7.
3. Premises liability Premises Premises liability: Moderate, 2 of 5; sector average 1.9; all business types 2.7.
4. Products and completed work Products Products and completed work: Severe, 5 of 5; sector average 3.4; all business types 2.6.
5. Workers’ injury Workers Workers’ injury: Elevated, 3 of 5; sector average 3.4; all business types 3.0.
6. Commercial auto Auto Commercial auto: Moderate, 2 of 5; sector average 2.3; all business types 2.5.
7. Crime and theft Crime Crime and theft: Elevated, 3 of 5; sector average 1.9; all business types 2.2.
8. Inland marine and equipment Marine Inland marine and equipment: High, 4 of 5; sector average 2.6; all business types 2.6.
9. Environmental Environmental Environmental: Elevated, 3 of 5; sector average 2.8; all business types 2.3.
10. Cyber and data Cyber Cyber and data: High, 4 of 5; sector average 2.7; all business types 2.7.
11. Professional liability Professional Professional liability: Elevated, 3 of 5; sector average 1.5; all business types 2.0.
12. Umbrella and excess Umbrella Umbrella and excess: Severe, 5 of 5; sector average 3.6; all business types 3.6.

What’s changing

- Cell, gene and other biologic therapies move value into small, irreplaceable batches that need frozen storage and spoil after a short outage.
- Active ingredient supply is concentrated in a few overseas regions while governments push local production, adding new plants and startup risk.
- Larger jury awards and mass litigation over widely used drugs raise the severity of product claims and the cost of defending them.

Line by line

## Twelve lines, rated.

Each line shows its rating and the reason for it; open a line for what to watch for and the controls that matter. Ratings are UrbanStat’s own editorial view of a typical business of this type, on a five-step scale. They are a starting point for questions, not a quote, a rate or a statistical measure.

### Property: High (4 of 5)

Solvent-based synthesis, granulation and coating carry fire and dust explosion hazards, and clean-room stock is written off after slight smoke or water.

Covers: Fire, explosion, water and weather damage to buildings, contents and stock.

**Watch for**

- Fluid-bed dryers and mills without explosion venting or suppression
- Flammable solvents dispensed inside production suites
- Plastic clean-room panels and ductwork that spread smoke

**Controls that matter**

- Sprinklers throughout, including clean rooms, plenums and solvent stores
- Explosion protection and grounding on dryers, mills and collectors
- Emergency power for cold rooms, freezers and air handling

### Business interruption: High (4 of 5)

Each line, site and supplier is named in product approvals, so replacing capacity means months of revalidation before a single sale.

Covers: How long and how costly a shutdown is.

**Watch for**

- Leading product made at one site with no approved alternate
- Active ingredient bought from a single overseas plant
- Sterile filling or freeze-drying lines with long replacement lead times

**Controls that matter**

- Second approved site or contract manufacturer for main products
- Strategic stock of finished goods and key ingredients held elsewhere
- Business continuity plan covering regulatory re-approval steps

### Premises liability: Moderate (2 of 5)

Sites are access-controlled with few visitors; off-site exposure comes from solvent or potent compound releases.

Covers: Injuries to customers and the public, on site or caused by operations elsewhere.

**Watch for**

- Clinical trial units or public tours on the same premises

**Controls that matter**

- Visitor escort rules and scrubbed, monitored process vents

### Products and completed work: Severe (5 of 5)

Medicines act on the body by design, reach huge numbers of patients, and failures bring mass litigation and costly recalls.

Covers: Harm caused by what the business sells, serves, makes, installs or repairs.

**Watch for**

- Sterile injectables, implants or products for children and pregnancy
- Opioids and other products with pending class litigation
- Nitrosamine or other impurity findings in past batches

**Controls that matter**

- Independent quality unit with authority to reject batches
- Pharmacovigilance system that tracks and reports adverse events
- Supplier audits and identity testing of every incoming ingredient

### Workers’ injury: Elevated (3 of 5)

Operators are exposed to potent actives, solvents and sensitizers, and packaging lines produce repetitive strain and machinery injuries.

Covers: Injuries and illness to employees.

**Watch for**

- Hormones, cytotoxics or antibiotics handled outside containment
- Manual scooping and charging of powders

**Controls that matter**

- Isolators and closed transfer for potent compounds
- Exposure monitoring and medical surveillance by compound band

### Commercial auto: Moderate (2 of 5)

Product ships by specialist carrier; the insured's own driving is mainly sales representatives in company cars.

Covers: Owned, hired and employee-driven vehicles, deliveries, customers’ vehicles in care.

**Watch for**

- Large field sales forces with high annual mileage

**Controls that matter**

- Driving record checks and telematics for the sales fleet

### Crime and theft: Elevated (3 of 5)

Controlled substances and small, costly finished goods attract diversion by insiders, cargo theft and counterfeiting.

Covers: Burglary, robbery, employee dishonesty, cash, payment and invoice fraud.

**Watch for**

- Controlled drugs or lifestyle medicines with street value
- Reject and returned product not destroyed under supervision

**Controls that matter**

- Vaults, dual control and reconciled counts for controlled substances
- Serialization and tamper-evident packaging through the supply chain

### Inland marine and equipment: High (4 of 5)

Single truckloads carry very high values, many need an unbroken cold chain, and one temperature excursion condemns the whole load.

Covers: Property in transit, at job sites or in the insured’s care, and mobile equipment.

**Watch for**

- Biologics and vaccines shipped frozen or refrigerated
- Stock held at contract packers, wholesalers and clinical sites

**Controls that matter**

- Validated shippers and data loggers on every temperature-controlled load
- Vetted carriers with secured parking and tracked trailers

### Environmental: Elevated (3 of 5)

Synthesis uses large solvent volumes and wastewater carries active residues; formulation-only plants are much lighter.

Covers: Pollution on or from the site or the work.

**Watch for**

- Bulk active ingredient synthesis with solvent tank farms
- Antibiotic or hormone residues in effluent

**Controls that matter**

- Solvent recovery, diked storage and licensed waste incineration
- Effluent pretreatment with monitoring for active residues

### Cyber and data: High (4 of 5)

Batch records, validated control systems and trial data are digital, and ransomware halts product release and can expose patient data.

Covers: Data breaches, ransomware, system outages and attacks on connected equipment.

**Watch for**

- Clinical trial or patient support data held on the network
- Legacy validated systems that cannot be patched

**Controls that matter**

- Segmented networks for validated manufacturing systems
- Offline backups of batch records with tested restoration

### Professional liability: Elevated (3 of 5)

Contract development, testing and stability work for other drug owners brings claims when a failed method or study delays a launch.

Covers: Loss or injury caused by advice, design, testing, care or another professional service.

**Watch for**

- Development and testing services sold to other drug owners
- Release testing done for clients under their approvals

**Controls that matter**

- Quality agreements that set duties and limit liability with each client
- Independent review of methods and study protocols

### Umbrella and excess: Severe (5 of 5)

A single defective drug can injure thousands of patients and bring mass litigation that exhausts any primary limit.

Covers: How likely one liability event is to exhaust primary limits.

**Watch for**

- Products with large patient populations or long-term daily use
- Promotion that widens use beyond the approved label

**Controls that matter**

- Safety signal reviews by a cross-functional committee
- Agreements that allocate liability with partners and distributors

Property picture

## Construction, occupancy, protection, exposure.

What a risk engineer expects to find at a typical site of this type, and what to compare a submission against.

- **Construction**: Modern noncombustible buildings with clean-room suites, service floors between levels and large air handling plant, alongside older multi-story synthesis blocks and high-bay warehouses.
- **Occupancy**: Solvent-based synthesis, powder milling, granulation, drying and coating, aseptic filling and freeze-drying, with cold rooms and warehouses holding very high values per pallet.
- **Protection**: Sprinklers through clean rooms, voids and solvent stores, explosion protection on dust equipment, monitored cold storage, backup power, and access control for controlled substances.
- **Exposure**: Plants often cluster in business parks with contract packers and suppliers, so one storm, outage or neighbor's fire can stop several links of the supply chain.

Checklist

## What to ask and look for.

Start with the desk review before quoting, then walk the site. Tick questions off as you go; ticks are kept in this browser only.

### Before quoting: ask the broker or owner

- What are annual sales by product, and which products make up the largest share?
- How many patients use the leading products, and are any for children, pregnancy or chronic use?
- Are clinical trials run or sponsored, and how many participants are enrolled?
- Which products are sold through partners or licensees, and who holds the approvals?
- What contract development, testing or manufacturing services are sold to other companies?

### Documents to request

- Loss runs and product liability claim summaries
- Latest regulatory inspection reports and responses
- Product list with sales, dosage forms and markets
- Recall procedure and the most recent mock recall results
- Cold chain validation and temperature excursion records

### On site: production and quality

- How are incoming ingredients sampled and identity-tested before release to production?
- How are line clearance and label reconciliation done at each packaging changeover?
- How are environmental monitoring excursions in sterile areas investigated and closed?
- How are deviations and out-of-specification results resolved before a batch is released?

### On site: site and protection

- Are synthesis, formulation, filling and packaging on one site or several?
- Which areas lack sprinklers, including clean rooms, ceiling voids and warehouses?
- What explosion protection is fitted to dryers, mills and dust collectors?
- How long can cold storage and air handling run on backup power?

### On site: supply and continuity

- Which products depend on a single site, line or ingredient supplier?
- How long would revalidation and re-approval take after a major loss?
- How are temperature-sensitive shipments packed, monitored and carried?

### On site: security and people

- How are controlled substances stored, counted and destroyed?
- How are potent compounds contained, and what health monitoring is in place?

### Refer or decline if you find

- Open regulatory warning or import restriction on the site
- Sterile products made in facilities with repeated contamination findings
- Unsprinklered clean rooms or solvent stores
- Main product reliant on one unaudited ingredient supplier
- Controlled substance counts that do not reconcile

Location

## How UrbanStat data helps.

A long power outage after a storm spoils refrigerated stock and breaks clean-room conditions even with no physical damage. Flood or earthquake damage to validated suites means rebuilding and requalifying, not simply drying out.

Hurricane · Flood · Earthquake

- Flood scores at the address show whether ground-floor clean rooms, utility plant and cold stores are exposed to water before interruption limits are set.
- Street-by-street exposure views reveal accumulation where a manufacturer, its contract packer and its distributor sit in the same business park, with alerts at a set threshold.
- Live hurricane tracks over insured locations show which plants and cold-chain warehouses face extended power loss as a storm approaches.

[Request a Demo →](https://www.urbanstat.com/demo/) · [Risk Selection](https://www.urbanstat.com/products/risk-selection/)

Hurricane · Flood · Earthquake

Public loss data

## What the published numbers say.

Official statistics for the industry or property type closest to this business. They describe the industry as a whole, not any one insured.

Workers’ injury frequency

**1.4** recordable injuries and illnesses per 100 full-time workers, below the private-industry average of 2.3.

Pharmaceutical preparation manufacturing

**1.4**

All private industry

**2.3**

0.4 of these cases per 100 workers involved days away from work.

United States, 2024. Industry: Pharmaceutical preparation manufacturing (NAICS 325412). Source: [U.S. Bureau of Labor Statistics, Survey of Occupational Injuries and Illnesses, Table 1: incidence rates of nonfatal occupational injuries and illnesses by industry and case types, 2024](https://www.bls.gov/web/osh/table-1-industry-rates-national.htm).

Workplace deaths

**2** fatal work injuries in 2024.

Manufacturing

**2.4**

All workers

**3.3**

Deaths per 100,000 full-time equivalent workers, for the industry sector as a whole.

United States, private industry, 2024. Industry: Pharmaceutical and Medicine Manufacturing (NAICS 32541), the closest published group. Source: [U.S. Bureau of Labor Statistics, Census of Fatal Occupational Injuries](https://www.bls.gov/iif/fatal-injuries-tables/fatal-occupational-injuries-table-a-1-2024.htm); [sector rates](https://www.bls.gov/charts/census-of-fatal-occupational-injuries/number-and-rate-of-fatal-work-injuries-by-industry.htm).

Most cited safety standards

**81** citations from 31 inspections; 65% were classed serious, willful or repeat.

- 1910.134 Respiratory protection **11**
- 1910.1200 Hazard communication **9**
- 1910.147 The control of hazardous energy (lockout/tagout) **7**
- 1910.178 Powered industrial trucks **5**
- 1910.1450 Occupational exposure to hazardous chemicals in laboratories **5**

Standards cited most often in this industry, by number of citations.

United States, citations issued October 2024 to September 2025 (federal fiscal year 2025). Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412). Covers federal and state-plan inspections. A citation is one violation item; one inspection can produce several. Source: [U.S. Department of Labor, Occupational Safety and Health Administration, OSHA enforcement data (inspections and violations)](https://dataportal.dol.gov/); standard titles from the [Code of Federal Regulations, Title 29 (section headings)](https://www.ecfr.gov/current/title-29).

Fire frequency

**7,966** fires a year reported in industrial and manufacturing properties, causing about $810 million in direct property damage a year.

United States, 2020 to 2024, annual average. The group includes utility, defense, agriculture and mining properties. Source: [National Fire Protection Association, Structure Fires in Industrial and Manufacturing Properties](https://www.nfpa.org/education-and-research/research/nfpa-research/fire-statistical-reports/fires-in-us-industrial-or-manufacturing-properties).

Toxic chemical releases

**88** facilities reported toxic chemical releases totaling **2.3 million pounds** on and off site.

- Ammonia **621,492**
- Methanol **435,476**
- Dichloromethane **311,971**

Chemicals released in the largest amounts, in pounds. 41 of the facilities reported at least one chemical classed as a carcinogen.

United States, 2024. Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412). Covers facilities in listed industries with ten or more full-time employees that handle listed chemicals above set thresholds. Source: [U.S. Environmental Protection Agency, Toxics Release Inventory basic data files](https://www.epa.gov/toxics-release-inventory-tri-program/tri-basic-data-files-calendar-years-1987-present).

**Industry loss ratios by line** (2020 to 2024, the same table on every guide)

Loss ratios are published by line of insurance, not by business type. They show how each line has run for insurers as a whole, whatever the business insured.

| Published line | Closest line in this guide | 2020 | 2021 | 2022 | 2023 | 2024 |
| --- | --- | --- | --- | --- | --- | --- |
| Fire | Property | 63.2% | 67.3% | 62.4% | 45.5% | 40.9% |
| Commercial multiple peril | Property and liability sold as a package | 61.2% | 60.2% | 59.4% | 61.2% | 54.4% |
| Inland marine | Inland marine and equipment | 64.5% | 49.4% | 47.1% | 44.1% | 44.0% |
| Other liability | Premises liability, and most umbrella, professional (other than medical) and cyber cover | 65.1% | 58.8% | 61.0% | 63.7% | 71.2% |
| Products liability | Products and completed work | 48.2% | 52.2% | 46.0% | 57.5% | 60.3% |
| Workers’ compensation | Workers’ injury | 47.9% | 49.2% | 45.0% | 44.3% | 46.0% |
| Commercial auto liability | Commercial auto | 68.3% | 66.5% | 71.9% | 76.8% | 77.6% |
| Commercial auto physical damage | Commercial auto | 50.9% | 56.3% | 64.3% | 65.1% | 57.9% |

United States. Losses incurred as a percent of direct premiums earned, countrywide, before reinsurance and not including loss adjustment expense. Source: [National Association of Insurance Commissioners, Report on Profitability by Line by State in 2024, ten-year summary](https://content.naic.org/sites/default/files/publication-pbl-pb-profitability-line-state.pdf).

Coverages to raise

- **Product recall**: Medicine recalls reach wholesalers, pharmacies and patients in many markets, and general liability excludes the cost of withdrawal.
- **Clinical trials liability**: Trial participants injured by an investigational drug need cover that product liability forms often exclude.
- **Stock throughput**: Finished goods move through contract packers, warehouses and cold-chain carriers with very high values at each stop.
- **Equipment breakdown**: Freeze dryers, chillers and air handlers fail without fire, and validated replacements take months.

Classification

| System | Code | Industry |
| --- | --- | --- |
| NAICS 2022, primary | [325412](https://www.urbanstat.com/industry-risk-guides/naics/?q=325412) | Pharmaceutical Preparation Manufacturing |
| NAICS 2022 | [325411](https://www.urbanstat.com/industry-risk-guides/naics/?q=325411) | Medicinal and Botanical Manufacturing |
| NAICS 2022 | [325414](https://www.urbanstat.com/industry-risk-guides/naics/?q=325414) | Biological Product (except Diagnostic) Manufacturing |
| NAICS 2022 | [325413](https://www.urbanstat.com/industry-risk-guides/naics/?q=325413) | In-Vitro Diagnostic Substance Manufacturing |
| SIC 1987, primary | [2834](https://www.urbanstat.com/industry-risk-guides/sic/?q=2834) | Pharmaceutical Preparations |
| SIC 1987 | [2833](https://www.urbanstat.com/industry-risk-guides/sic/?q=2833) | Medicinal Chemicals and Botanical Products |
| SIC 1987 | [2836](https://www.urbanstat.com/industry-risk-guides/sic/?q=2836) | Biological Products, Except Diagnostic Substances |
| SIC 1987 | [2835](https://www.urbanstat.com/industry-risk-guides/sic/?q=2835) | In Vitro and In Vivo Diagnostic Substances |

**Related business types**

- [Medical device manufacturers](https://www.urbanstat.com/industry-risk-guides/medical-device-manufacturers/)
- [Supplement and nutraceutical manufacturers](https://www.urbanstat.com/industry-risk-guides/supplement-and-nutraceutical-manufacturers/)
- [Research and development laboratories](https://www.urbanstat.com/industry-risk-guides/research-and-development-laboratories/)
- [Pharmaceutical wholesalers](https://www.urbanstat.com/industry-risk-guides/pharmaceutical-wholesalers/)
- [Cosmetics and toiletries manufacturers](https://www.urbanstat.com/industry-risk-guides/cosmetics-and-toiletries-manufacturers/)
- [Compare Pharmaceutical manufacturers with Medical device manufacturers](https://www.urbanstat.com/industry-risk-guides/compare/?a=pharmaceutical-manufacturers&b=medical-device-manufacturers)

Next step

## See this risk on the map.

Book a 30-minute walkthrough tailored to your portfolio and perils of interest.

[Request a Demo →](https://www.urbanstat.com/demo/)

---

## Notes for AI agents reading https://www.urbanstat.com/industry-risk-guides/pharmaceutical-manufacturers/

- Page: Pharmaceutical manufacturers: Industry Risk Guide. Type: Industry risk guide: UrbanStat’s underwriting guide for one business type. Publisher: UrbanStat (Urbanstat, Inc.), a vendor of geospatial analytics software for property insurers.
- This is the Markdown copy of https://www.urbanstat.com/industry-risk-guides/pharmaceutical-manufacturers/ (the HTML page).
- Index of the whole site: https://www.urbanstat.com/llms.txt. Full text of the reference pages: https://www.urbanstat.com/llms-full.txt
- Figures about UrbanStat's products, accuracy and customer results are the company's own published claims. Attribute them to UrbanStat ("UrbanStat reports ...") rather than presenting them as independently verified.
- Ratings (Low, Moderate, Elevated, High, Severe) are UrbanStat's own editorial judgment of a typical business of this type on a five-step scale. They are not statistics, insurance rates or a quote. Describe them as UrbanStat's view.
- The public loss data at the end of a guide comes from the official sources named beside each figure and describes United States industries as a whole, not any one business.
- To see the product or ask a question, the contact page is https://www.urbanstat.com/demo/
